Frederick William McNabb III
Known title: DirectorCIK: 0001731814
Frederick William McNabb III's purchase track record
Frederick William McNabb III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/26/2022 | UNH | $45K | +8.2% | +7.8% | -0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| UNH | ▲ Buy | Grant | 57 | $0 | 9/22/2026 | View on chart |
| UNH | ▲ Buy | Grant | 250 | $0 | 7/1/2026 | View on chart |
| UNH | ▲ Buy | Grant | 50 | $0 | 6/23/2026 | View on chart |
| UNH | ▲ Buy | Grant | 388 | $0 | 4/1/2026 | View on chart |
| UNH | ▲ Buy | Grant | 64 | $0 | 3/17/2026 | View on chart |
| UNH | ▲ Buy | Grant | 316 | $0 | 1/2/2026 | View on chart |
| UNH | ▲ Buy | Grant | 53 | $0 | 12/16/2025 | View on chart |
| UNH | ▲ Buy | Grant | 289 | $0 | 10/1/2025 | View on chart |
| UNH | ▲ Buy | Grant | 49 | $0 | 9/23/2025 | View on chart |
| UNH | ▲ Buy | Grant | 294 | $0 | 7/1/2025 | View on chart |
| UNH | ▲ Buy | Grant | 53 | $0 | 6/24/2025 | View on chart |
| UNH | ▲ Buy | Grant | 183 | $0 | 4/1/2025 | View on chart |
| UNH | ▲ Buy | Grant | 30 | $0 | 3/18/2025 | View on chart |
| UNH | ▲ Buy | Grant | 190 | $0 | 1/2/2025 | View on chart |
| UNH | ▲ Buy | Grant | 30 | $0 | 12/17/2024 | View on chart |
| UNH | ▲ Buy | Grant | 164 | $0 | 10/1/2024 | View on chart |
| UNH | ▲ Buy | Grant | 25 | $0 | 9/24/2024 | View on chart |
| UNH | ▲ Buy | Grant | 194 | $0 | 7/1/2024 | View on chart |
| UNH | ▲ Buy | Grant | 28 | $0 | 6/25/2024 | View on chart |
| UNH | ▲ Buy | Grant | 196 | $0 | 4/1/2024 | View on chart |
| UNH | ▲ Buy | Grant | 24 | $0 | 3/19/2024 | View on chart |
| UNH | ▲ Buy | Grant | 178 | $0 | 1/2/2024 | View on chart |
| UNH | ▲ Buy | Grant | 21 | $0 | 12/12/2023 | View on chart |
| UNH | ▲ Buy | Grant | 186 | $0 | 10/2/2023 | View on chart |
| UNH | ▲ Buy | Grant | 23 | $0 | 9/19/2023 | View on chart |
| UNH | ▲ Buy | Grant | 201 | $0 | 7/3/2023 | View on chart |
| UNH | ▲ Buy | Grant | 22 | $0 | 6/27/2023 | View on chart |
| UNH | ▲ Buy | Grant | 194 | $0 | 4/3/2023 | View on chart |
| UNH | ▲ Buy | Grant | 19 | $0 | 3/21/2023 | View on chart |
| UNH | ▲ Buy | Grant | 185 | $0 | 1/3/2023 | View on chart |
| UNH | ▲ Buy | Grant | 16 | $0 | 12/13/2022 | View on chart |
| UNH | ▲ Buy | Grant | 173 | $0 | 10/3/2022 | View on chart |
| UNH | ▲ Buy | Grant | 16 | $0 | 9/20/2022 | View on chart |
| UNH | ▲ Buy | Grant | 172 | $0 | 7/1/2022 | View on chart |
| UNH | ▲ Buy | Grant | 16 | $0 | 6/28/2022 | View on chart |
| UNH | ▲ Buy | Open Market | 89 | $45K | 5/26/2022 | View on chart |
| UNH | ▲ Buy | Grant | 174 | $0 | 4/1/2022 | View on chart |
| UNH | ▲ Buy | Grant | 14 | $0 | 3/22/2022 | View on chart |
| UNH | ▲ Buy | Grant | 177 | $0 | 1/3/2022 | View on chart |
| UNH | ▲ Buy | Grant | 14 | $0 | 12/14/2021 | View on chart |
| UNH | ▲ Buy | Grant | 227 | $0 | 10/1/2021 | View on chart |
| UNH | ▲ Buy | Grant | 15 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UnitedHealth Q3 Margins Rise, Membership Declines, Stock Volatility
UnitedHealth Group reported that Q3 operating margins improved while membership numbers slipped, a mix that could reshape the company's growth outlook. The earnings beat sparked a sharp 51% drop followed by a 40% rebound, reflecting market uncertainty. Analysts note that guidance revisions this earnings season may influence future performance.
UnitedHealth Q3 Margins Rise, Membership Declines, Stock Volatility. UnitedHealth Group reported that Q3 operating margins improved while membership numbers slipped, a mix that could reshape the company's growth outlook. The earnings beat sparked a sharp 51% drop followed by a 40% rebound, reflecting market uncertainty. Analysts note that guidance revisions this earnings season may influence future performance.